Synexa Life Sciences (Group)

https://www.synexagroup.com

LinkedIn: https://www.linkedin.com/company/synexa-life-sciences

For nearly 20 years Synexa Life Sciences has supported leading biopharma clients across the globe to achieve their clinical milestones through the application of cutting-edge biomarker science. Synexa specialises in the development, validation and delivery of a wide range of complex and custom-designed assays, founded on deep expertise in immunology and the impact of the immune system on human health and candidate drug performance. Synexa is backed by Gilde Healthcare, a leading European healthcare investor managing funds of over €1.9 billion. *

	Start	2003-01-01 established
	Industry	contract research (drugs)
	Industry 2	biomarker discovery services
	Person	Lens, Emile (Synexa Life Sciences 202205 CEO before Avania + Maxeda DIY + ABN AMRO)
	Person 2	Borchards, Nadia (Synexa Life Sciences 202205c– CFO)

	Region	Leiden
	Country	Netherlands
	Street	32 Mendelweg Leiden Bio Science Park, 107 Regus Building
	City	2333 CS Leiden
	Tel	+31-71-760-1644
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Synexa Life Sciences B.V.. (5/19/22). "Press Release: Synexa Life Sciences Acquires Finnish CRO Syrinx Bioanalytics to Expand Bioanalysis Capabilities". Leiden.

		Record changed: 2024-02-12